NexCAR19 (talicabtagene autoleucel, Tali‑cel™)
CD19‑positive B‑cell acute lymphoblastic leukemia and large B‑cell lymphoma
CommercialActive
Key Facts
Indication
CD19‑positive B‑cell acute lymphoblastic leukemia and large B‑cell lymphoma
Phase
Commercial
Status
Active
Company
About ImmunoACT
India’s first indigenous CAR‑T developer delivering low‑cost, GMP‑grade therapies for B‑cell cancers.
View full company profile